Carlyle Group and SK Capital Partners to acquire bluebird bio for $96m.

Private equity firms Carlyle Group and SK Capital Partners to acquire bluebird bio, a biotechnology company specializing in gene therapies, for $96m. "This acquisition represents the best path forward—maximizing value for stockholders and bringing significant capital, commercial expertise, and a commitment to provide more patients the opportunity to benefit from potentially transformative gene therapies," Andrew Obenshain, bluebird bio CEO.